Recent investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are demonstrating encouraging effects in managing obesity and type second-type disease. Preclinical data suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/